Rebecca Redman, MD

Rebecca Redman, MD

Education:

MD, University of Wisconsin Medical School 2003
Residency, Internal Medicine, University of North Carolina 2006
Fellowship, Medical Oncology and Hematology, Duke University 2010
Board Certified, ABIM, Hematology, 2010
Board Certified, ABIM, Medical Oncology, 2010

Curriculum Vitae

Current Positions:

Assistant Professor of Medicine, Department of Medicine
Associate Director, Brown Cancer Center Clinical Trials Office
Director, Medical Oncology Service, Head  and Neck Cancer Multidisciplinary Clinic

Clinical Focus and Research:

My clinical focus is on multi-disciplinary approaches to the treatment of Head and Neck cancers and Gastrointestinal (Colorectal, Anal, Pancreas, Liver, Esophagus, Gastric) cancers.  I work with surgical and radiation oncologists to ensure that my patients receive the most effective combination of treatment modalities and have access to the most innovative drugs for the treatment of cancer.

My research interests include clinical trials of new chemotherapeutics and targeted agents, identification of barriers to treatment, and novel approaches to mitigate toxicities of chemotherapy and radiation.  In particular, I am focused on phase I trials of small molecules that target the metabolism of cancer cells (i.e. PFK-158) (1, 2) and the use of plant-based exosomes to reduce the inflammation caused by radiation (3).  I also conduct industry-sponsored trials and National Cancer Institute-funded cooperative group trials so that my patients have access to novel immunotherapeutic and targeted agents.

Literature Cited:

  1. Clem, B.F., O’Neal, J., Tapolsky, G., Clem, A., Imbert-Fernandez, Y., Klarer, A. C, Redman, R., Trent, J.O., Telang, S. and Chesney, J. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Molecular Cancer Therapeutics (AACR) 12(8), 1-10, 2013.  PMID: 23674815.  http://www.ncbi.nlm.nih.gov/pubmed/?term=redman+r+and+phosphfructo
  2. Redman, R.  Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies.  Clinicaltrials.gov #NCT02044861.  http://clinicaltrials.gov/ct2/show/NCT02044861?term=pfk-158&rank=1
  3. Redman, R. Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients.  Clinicaltrials.gov #NCT01668849.  
    http://clinicaltrials.gov/ct2/show/NCT01668849?term=Redman+and+grape&rank=1

PubMed Information